List view / Grid view
6 January 2016 | By Victoria White
The Phase 1 study, initiated by Washington University, will evaluate VS-6063 in combination with pembrolizumab and gemcitabine in patients with pancreatic cancer...
6 January 2016 | By Victoria White
Pharming has completed patient enrolment in the Phase 2 clinical study of Ruconest (recombinant C1 esterase Inhibitor, 50 IU/kg) for prophylaxis in patients with hereditary angioedema (HAE).
6 January 2016 | By Victoria White
The objective of the Phase 1 study is to evaluate the safety and tolerability of ARGX-113 and to identify a potential dose for future Phase 2 studies...
6 January 2016 | By Victoria White
The studies demonstrated that TAF was non-inferior to Gilead’s Viread (tenofovir disoproxil fumarate, TDF) based on the percentage of patients with HBV DNA levels below 29 IU/mL at 48 weeks of therapy...
6 January 2016 | By Victoria White
Newly presented data from the largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab...
5 January 2016 | By Victoria White
GBI Research states that this strong growth will be primarily due to substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise over the forecast period due to an aging population, changing lifestyles and higher survival rates...
5 January 2016 | By Victoria White
IONIS-HTTRx is a Gen. 2.0+ antisense drug in development for the treatment of Huntington's disease...
5 January 2016 | By Victoria White
The minimal increase over the next decade will be largely the product of a treatment space dominated by three primary agents, namely vancomycin, Zyvox (linezolid), and Cubicin (daptomycin)...
5 January 2016 | By Victoria White
CAR-NKG2D is a chimeric antigen receptor (CAR) T-Cell autologous therapy that has the potential to target ligands present on a broad range of solid tumours and blood cancers...
5 January 2016 | By Victoria White
Baremsis comprises a low dose intravenous formulation of the marketed dopamine antagonist amisulpride, which Acacia Pharma has repurposed for the management of PONV...
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
4 January 2016 | By Victoria White
Since 2005, MHRA officials have found hundreds of examples of medicines claiming to contain herbal ingredients but after analysis were found to be adulterated with pharmaceutical ingredients...
4 January 2016 | By Victoria White
ThermiGen is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications...
4 January 2016 | By Victoria White
GlobalData says this rise will be driven primarily by the introduction of premium-priced therapies for advanced gastric cancer and, as a consequence, the increased uptake of therapy and lengthier treatment duration...
4 January 2016 | By HORIBA Scientific
Joint HORIBA and AIST-NT solution provided spatial resolution below 15 nm...
